Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Craig Leonardi

Showing results (41-50 of 49) with videos related to

Pageof 5
Sort By:
You have reached the last page of results.This site can display upto 49 results.
Dermatology and Therapy|July 7, 2022
Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-AnalysisApril Armstrong, Kyle Fahrbach, Craig Leonardi, et al.
Journal of the American Academy of Dermatology|December 29, 2016
Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trialsKristian Reich, Craig Leonardi, Richard G Langley, et al.
Plos One|November 12, 2015
A Randomized, Placebo-Controlled Study of SRT2104, a SIRT1 Activator, in Patients with Moderate to Severe PsoriasisJames G Krueger, Mayte Suárez-Fariñas, Inna Cueto, et al.
Journal of Drugs in Dermatology : JDD|February 21, 2018
Safety and Tolerability of Ixekizumab: Integrated Analysis of Injection-Site Reactions from 11 Clinical TrialsNeil H Shear, Carle Paul, Andrew Blauvelt, et al.
Journal of the American Academy of Dermatology|October 3, 2006
Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension studyKenneth B Gordon, Richard G Langley, Craig Leonardi, et al.
The Journal of Dermatological Treatment|October 5, 2010
Improving clinical trial design in psoriasis: Perspectives from the global dermatology communityPeter van de Kerkhof, Jonathan Barker, Christopher E M Griffiths, et al.
Journal of the American Academy of Dermatology|November 28, 2016
Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated dataBruce Strober, Craig Leonardi, Kim A Papp, et al.
Journal of Drugs in Dermatology : JDD|May 12, 2016
Efficacy of Tofacitinib for the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis in Patient Subgroups from Two Randomised Phase 3 TrialsM Alan Menter, Kim A Papp, Jennifer Cather, et al.
Dermatology and Therapy|March 23, 2020
Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled TrialsCraig Leonardi, Kristian Reich, Peter Foley, et al.
Pageof 5

Showing results (41-50 of 49) with videos related to

Sort By:
Pageof 5
You have reached the last page of results.This site can display upto 49 results.
Dermatology and Therapy|July 7, 2022
Efficacy of Bimekizumab and Other Biologics in Moderate to Severe Plaque Psoriasis: A Systematic Literature Review and a Network Meta-AnalysisApril Armstrong, Kyle Fahrbach, Craig Leonardi, et al.
Journal of the American Academy of Dermatology|December 29, 2016
Inflammatory bowel disease among patients with psoriasis treated with ixekizumab: A presentation of adjudicated data from an integrated database of 7 randomized controlled and uncontrolled trialsKristian Reich, Craig Leonardi, Richard G Langley, et al.
Plos One|November 12, 2015
A Randomized, Placebo-Controlled Study of SRT2104, a SIRT1 Activator, in Patients with Moderate to Severe PsoriasisJames G Krueger, Mayte Suárez-Fariñas, Inna Cueto, et al.
Journal of Drugs in Dermatology : JDD|February 21, 2018
Safety and Tolerability of Ixekizumab: Integrated Analysis of Injection-Site Reactions from 11 Clinical TrialsNeil H Shear, Carle Paul, Andrew Blauvelt, et al.
Journal of the American Academy of Dermatology|October 3, 2006
Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind, randomized controlled trial and open-label extension studyKenneth B Gordon, Richard G Langley, Craig Leonardi, et al.
The Journal of Dermatological Treatment|October 5, 2010
Improving clinical trial design in psoriasis: Perspectives from the global dermatology communityPeter van de Kerkhof, Jonathan Barker, Christopher E M Griffiths, et al.
Journal of the American Academy of Dermatology|November 28, 2016
Short- and long-term safety outcomes with ixekizumab from 7 clinical trials in psoriasis: Etanercept comparisons and integrated dataBruce Strober, Craig Leonardi, Kim A Papp, et al.
Journal of Drugs in Dermatology : JDD|May 12, 2016
Efficacy of Tofacitinib for the Treatment of Moderate-to-Severe Chronic Plaque Psoriasis in Patient Subgroups from Two Randomised Phase 3 TrialsM Alan Menter, Kim A Papp, Jennifer Cather, et al.
Dermatology and Therapy|March 23, 2020
Efficacy and Safety of Ixekizumab Through 5 Years in Moderate-to-Severe Psoriasis: Long-Term Results from the UNCOVER-1 and UNCOVER-2 Phase-3 Randomized Controlled TrialsCraig Leonardi, Kristian Reich, Peter Foley, et al.
Pageof 5